A Study of Talimogene Laherparepvec (T-VEC) in Combination With Pembrolizumab in Patients With Metastatic and/or Locally Advanced Sarcoma
A Study of Talimogene Laherparepvec (T-VEC) in Combination With Pembrolizumab in Patients With Metastatic and/or Locally Advanced Sarcoma
Active, not recruiting · NCT03069378 · Registry updated 2026-07-17Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| A Study of Talimogene Laherparepvec (T-VEC) in Combination With Pembrolizumab in Patients With Metastatic and/or Locally Advanced Sarcoma | Neoplasm Metastasis, Neoplasms by Histologic Type, Neoplasms, Connective and Soft Tissue, Neoplastic Processes, Pathologic Processes, Pathological Conditions, Signs and Symptoms, neoplasm, sarcoma | Active, not recruiting | Phase 2 | 2026-07-17 | NCT03069378 |
3 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Amgen | 180 |
| Memorial Sloan Kettering Cancer Center | 753 |
| Merck Sharp & Dohme LLC | 650 |
5 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Enable Medicine (Specimen Analysis Only) | Menlo Park | United States | 1 |
| MD Anderson Cancer Center (Data Analysis Only) | Houston | United States | 2 |
| Memorial Sloan Kettering Cancer Center | New York | United States | 1000 |
| Memorial Sloan Kettering Westchester (Limited Protocol Activities) | Harrison | United States | 166 |
| Stanford University Medical Center | Stanford | United States | 4 |